



YINDA INFOCOMM LIMITED
(Company Registration No.: 201506891C)
(Incorporated in the Republic of Singapore)

Responses to SGX Queries received on 16 November 2020

The Board of Directors (the “**Board**”) of Yinda Infocomm Limited (the “**Company**”) refers to the Company’s announcement on 15 November 2020 in relation to the proposed subscription of 81,200,000 new ordinary shares in the capital of the Company at a subscription price of S\$0.072 per share (“**Nov Placement Announcement**”).

The Company has on 16 November 2020 received the following queries from the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”), and sets out its response below. All capitalised terms used herein shall have the same meanings as ascribed to them in the Nov Placement Announcement.

Query 1: We refer to the announcement by Yinda Infocomm Limited (the "Company"), in relation to a S\$5.8 million Proposed Placement (the "Nov Placement").

In October 2020, the Company has completed a S\$3.8 million Placement (the "Oct Placement").

The use of proceeds for these two placements are similar, namely for working capital and new business opportunities.

Please disclose the specific use of proceeds of the Oct Placement that was utilized.

As at the date of this announcement, the use of net proceeds from the Oct Placement are as follows:

Use of Net Proceeds from the Oct Placement	Amount allocated (S\$'000)	Amount utilised (S\$'000)	Amount remaining (S\$'000)
Working Capital	1,131 – 1,508	(341)	790 – 1,167
New Business Opportunities	2,262 – 2,639	(50)	2,212 – 2,589
Total	3,770	(391)	3,379

A breakdown of the net proceeds from the Oct Placement that was utilised for working capital are:

	Working Capital
	(S\$)
Summary of expenses:	

Listing fees	(16,585)
Staff cost	(60,867)
Finance cost or bank charges	(2,815)
Professional fees	(247,139)
Administrative expenses	(14,077)
Total	(341,483)

Query 2: On 1 November 2020, the Company announced its entry into a non-binding MOU to acquire 51% interest in International Biometrics Pte. Ltd (the "Interbio Acquisition").

Does the Company intend to use the proceeds from both Oct Placement and Nov Placement for the Interbio Acquisition?

As stated in paragraphs 5.2 of the Oct Placement announcement dated 29 September 2020 and the Nov Placement Announcement, the Board and Management has allocated around 60% to 70% of the net proceeds from the Oct Placement amounting to S\$2.3 million to S\$2.6 million and 70% to 80% of the net proceeds from the Nov Placement amounting to S\$4.1 million to S\$4.6 million for the purposes of new business opportunities, which includes but is not limited to the Interbio Acquisition.

The Company is still in the midst of performing the necessary due diligence process on the Interbio Acquisition and there is no certainty that the Interbio Acquisition will proceed to fruition. Depending on the results of the due diligence and the commercial negotiations between the Company and the vendors of the Interbio Acquisition, the Company may use proceeds from both the Oct Placement and Nov Placement for the Interbio Acquisition.

The Company will make the appropriate announcements when the proceeds from the Oct Placement and Nov Placement are materially disbursed.

By order of the Board

Mdm. Song Xingyi
Non-Executive and Non-Independent Chairman

17 November 2020

This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Ong Hwee Li (Tel +65 6232 3210), at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.